NTT Biopharma’s proprietary Mesoporous Silica Nanoparticle (MSN) Drug Delivery Platform has been recognized with the 22nd National Innovation Award, in acknowledgment of its innovative value in overcoming critical drug delivery barriers and addressing significant unmet medical needs.
The MSN drug delivery platform developed by NTT Biopharma features an ultrasmall particle size, highly customizable properties, and exceptional capabilities in biological barrier penetration and tumor targeting. This technology effectively traverses major physiological barriers, including the blood–brain barrier (BBB) and the blood–ocular barrier (BOB), thereby substantially expanding therapeutic possibilities for diseases that have long been considered challenging or undruggable due to delivery limitations. These include central nervous system disorders such as brain cancer, refractory cancers such as metastatic colorectal cancer, and retinal diseases such as macular degeneration, enabled by eye-drop formulations.
Several product candidates have completed key preclinical studies, and NTT Biopharma is actively collaborating with domestic and international partners to accelerate the development of MSN-based nanomedicines. The lead program, NTT-001 for primary and metastatic brain cancer, is preparing to enter clinical trials, highlighting the company’s translational strength in nanomedicine innovation.
This award not only underscores NTT Biopharma’s technological breakthroughs in nanomedicine-based drug delivery but also further accelerates the global advancement of Taiwan’s innovative drug delivery platform technologies.
---
奈力生醫(NTT Biopharma)自主研發的「中孔洞二氧化矽奈米粒子(Mesoporous Silica Nanoparticle, MSN)藥物傳輸平台技術」在突破藥物傳輸瓶頸與解決未滿足醫療需求上的創新價值，榮獲第22屆國家新創獎—企業新創獎肯定。
奈力生醫所開發的MSN藥物傳輸平台技術具備超小粒徑、客製化特性與優異生物屏障穿透及腫瘤標靶能力，可有效跨越血腦屏障與血眼屏障等，大幅拓展中樞神經系統疾病(如腦癌)、難治型癌症(如轉移性大腸癌)與視網膜疾病(如眼藥水劑型治療黃斑部病變)等過去被視為「因藥物傳輸侷限而無法有效治療的疾病」其治療可能性，帶來突破性的奈米藥物治療契機。
目前多項產品已完成關鍵臨床前驗證，並且與多家國內外生技醫藥公司合作，加速推進MSN奈米藥物之發展。其中領頭產品NTT-001用於治療原位及轉移性腦癌即將申請進行臨床試驗，展現兼具科學創新與臨床轉譯潛力的奈米醫藥研發實力。此次獲獎不僅肯定奈力生醫在奈米藥物傳輸領域的技術突破，也推動台灣創新生醫技術邁向國際舞台。
相關連結: https://innoaward.taiwan-healthcare.org/photo_detail.php?REFDOCTYPID=0t7i02gg37jx5xwg&REFDOCID=0t7i02gg37jx5xwg